American Journal of Cancer Prevention
ISSN (Print): 2328-7314 ISSN (Online): 2328-7322 Website: http://www.sciepub.com/journal/ajcp Editor-in-chief: Nabil Abdel-Hamid
Open Access
Journal Browser
Go
American Journal of Cancer Prevention. 2015, 3(5), 103-105
DOI: 10.12691/ajcp-3-5-8
Open AccessResearch Article

The Survival of Nodal Non-Hodgkin’s Lymphoma Patients in the West of Iran

Mehrdad Payandeh1, Masoud Sadeghi1, 2, , Ali Shahriari-Ahmadi3 and Edris Sadeghi1, 2

1Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

3Rasool-Akram Hospital, Oncology and Hematology ward, Iran University of Medical Sciences, Tehran, Iran

Pub. Date: October 08, 2015
(This article belongs to the Special Issue Advances in Non-Hodgkin Lymphomas)

Cite this paper:
Mehrdad Payandeh, Masoud Sadeghi, Ali Shahriari-Ahmadi and Edris Sadeghi. The Survival of Nodal Non-Hodgkin’s Lymphoma Patients in the West of Iran. American Journal of Cancer Prevention. 2015; 3(5):103-105. doi: 10.12691/ajcp-3-5-8

Abstract

Background: Most non-Hodgkin’s lymphomas (NHL) arise in lymph nodes or other lymphatic tissues such as the spleen, Waldeyer’s ring and thymus. The aim of study is to evaluate the survival in nodal NHL patients for the first time in the west of Iran. Patients and Methods: Fifty-three patients with nodal NHL referred to Our Clinic from 2002-2014. We checked age, sex, histopathology reports, anatomic sites and survival for them. One representative Material of patients with diffuse large B-cell lymphoma (DLBL), FL, SLL and anaplastic lymphoma was re-classified after revision. The overall survival (OS) was plotted by GraphPad Prism 5 software. Results: For all patients, the median age at diagnosis was 52±16.92 (range, 16-92 years) that 26 patients (49.1%) had age≤50 years. Thirty-four patients (64.2%) were male. Involvement anatomic sites were axillary, neck, inguinal, cervical, mediasten, bone marrow, abdominal, bladder, tonsil and supraclavicular for 11 patients (20.6%), 9(17%), 9(17%), 8(15.2%), 6(11.3%), 5(9.4%), 2(3.8%), 1(1.9%), 1(1.9%) and 1(1.9%), respectively. The 3-year, 5-year and 10-year survival rates are 65%, 54.2% and 51%, respectively. Conclusion: The OS in this study is higher than a number of studies and the median age is lower. Also, the male-to-female ratio for nodal lymphoma is higher than other studies and nodal NHL patients accrue more in males.

Keywords:
NHL nodal lymphoma overall survival DLBCL

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer. 1997. 72 (6): 923-30.
 
[2]  Krol AD, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol. 2003. 14 (1): 131-9.
 
[3]  Ferry JA. Extranodal lymphoma. Arch Pathol Lab Med. 2008. 132 (4): 565-78.
 
[4]  Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol. 1996. 14 (7): 2131-8.
 
[5]  Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, et al.Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998. 92 (9): 3152-62.
 
[6]  Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
 
[7]  Hashmi AA, Hussain ZF, Faridi N, Khurshid A. Distribution of Ki67 proliferative indices among WHO subtypes of non-Hodgkin's lymphoma: association with other clinical parameters. Asian Pac J Cancer Prev. 2014. 15 (20): 8759-63.
 
[8]  Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988. 6 (12): 1838-44.
 
[9]  Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, et al. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer. 1989. 59 (2): 276-82.
 
[10]  Krol AD, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol. 2003. 14 (1): 131-9.
 
[11]  Karadeniz C, Oguz A, Citak EC, Uluoglu O, Okur V, Demirci S, et al. Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center. Pediatr Hematol Oncol. 2007. 24 (6): 417-30.
 
[12]  Laurent C, Do C, Gourraud PA, de Paiva GR, Valmary S, Brousset P. Prevalence of Common Non-Hodgkin Lymphomas and Subtypes of Hodgkin Lymphoma by Nodal Site of Involvement: A Systematic Retrospective Review of 938 Cases. Medicine (Baltimore). 2015. 94 (25): e987.